UNSPSC 51282208: Cefoxitin sodium

This classification denotes a cephalosporin antibiotic with the molecular formula C16H16N3O7S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q68050H03T, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, sodium salt, (6r-cis)- but more generally known as cefoxitin sodium, which bears US NIH Compound Identifier 36551.

UNSPSC 51282208 Cefoxitin sodium, a Commodity code, shows minimal recent state and local procurement activity directly aligned with the code's pharmaceutical scope. The three recent opportunities posted under or near this code—naloxone and drug deactivation systems procurement, a pharmacy benefit management RFI, and medical and first aid supplies for emergency response—do not target cefoxitin sodium or other injectable antibiotics. The code's nominal scope describes a specific narrow-spectrum antibiotic used in clinical and surgical settings, but the recent solicitations reflect broader pharmaceutical and medical supply categories. State and local buyers using this code appear to source through group purchasing arrangements and cooperative vehicles rather than direct competitive bidding for individual pharmaceutical commodities.

Geographic activity appears concentrated in Florida and Minnesota through cooperative purchasing frameworks. Seminole County, Florida issued an IFB for naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2026), and the City of Tampa solicited medical and first aid supplies for its Fire Department Rescue Division (ITB 26P00145, due March 13, 2026, estimated $700,000, sheltered for certified Small Local Business Enterprises). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP for generic multi-source pharmaceuticals and OTC products distributed to participating state and local facilities including Oregon (RFP S1070000015802, proposals due March 26, 2026). Texas Health and Human Services Commission posted an RFI on direct-to-manufacturer pharmacy prescription programs (HHS0017013, April 3, 2026), signaling exploratory procurement in that state. Cefoxitin sodium itself does not appear in the recent posted opportunities; buyers pursuing this code should monitor cooperative purchasing vehicles and hospital system procurements rather than expect frequent standalone solicitations.